Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trial Profile

ONO-4538 Phase I Study - A Single Center, Open Label, Dose Escalation Single Dose, Followed by Multiple Dose Study of ONO-4538, a Fully Human mAb to PD-1, in Patients With Advanced Malignant Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Ono Pharmaceutical

Most Recent Events

  • 01 Nov 2018 Results of ONO-4538-01, ONO-4538-02, ONO-4538-04, ONO-4538-05, ONO-4538-06, and ON-4538-08 evaluating risk factors and the clinical course of Thyroid Dysfunction induced by nivolumab, published in the Cancer Science.
  • 19 Oct 2018 Results of a pooled population pharmacokinetics and exposure-safety analysis from 9 studies, published in the Journal of Clinical Pharmacology.
  • 08 Dec 2016 Results published in the Investigational New Drugs

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days